Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer

Toxicology and Applied Pharmacology

Volumn 338, Issue , 2018, Pages 83-92

  Waidyanatha, Suramya ^a   Toy, Heather ^b   South, Natalie ^b   Gibbs, Seth ^b   Mutlu, Esra ^a   Burback, Brian ^b   McIntyre, Barry S ^a   Catlin, Natasha ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOVINCAMINIC ACID; VINPOCETINE; VINCA ALKALOID;

AMNION FLUID; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ELIMINATION HALF-LIFE; FEMALE; FETUS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLACENTAL TRANSFER; PREGNANCY; RAT; SPRAGUE DAWLEY RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS; VOLUME OF DISTRIBUTION; ANIMAL; FETOMATERNAL TRANSFUSION; METABOLISM;

AMNIOTIC FLUID; ANIMALS; AREA UNDER CURVE; FEMALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; VINCA ALKALOIDS;

EID: 85034607503     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2017.11.011     Document Type: Article

References (33)

1. Anonymous, Cavinton, injection, tablet. Geor. Med. 14 (1984), 363–364.
2. Bereczki, D., Fekete, I., Vinpocetine for acute ischemic stroke. Cochrane Database Syst. Rev., 1, 2008, CD000580.
3. Cholnoky, E., Dömök, L.I., Summary of safety tests of ethyl apovincaminate. Arzneimittelforschung 26 (1976), 1938–1944.
4. Davies, B., Morris, T., Physiological parameters in laboratory animals and humans. Pharm. Res. 10 (1993), 1093–1095.
5. Elbary, A.A., Foda, N., El-Gazayerly, O., El Khatib, M., Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application. Anal. Lett. 35 (2002), 1041–1054.
6. Feigin, V.L., Doronin, B.M., Popova, T.F., Gribatcheva, E.V., Tchervov, D.V., Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur. J. Neurol. 8 (2001), 81–85.
7. Grandt, R., Beitinger, H., Schaltenbrand, R., Braun, W., Vinpocetine pharmacokinetics in elderly subjects. Arzneimittelforschung 39 (1989), 1599–1602.
8. Kharshoum, R.M., Sanad, R.A., Ali, A.M.A., Comparative pharmacokinetic study of two lyophilized orally disintegrating tablets formulations of vinpocetine in human volunteers. Int. J. Drug Deliv. 5 (2013), 167–176.
9. Lohmann, A., Dingler, E., Sommer, W., Schaffler, K., Wober, W., Schmidt, W., Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung 42 (1992), 914–917.
10. Maconi, E., Binaghi, F., Pitzus, F., A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr. Ther. Res. 40 (1986), 702–709.
11. Miskolczi, P., Kozma, K., Polgar, M., Vereczkey, L., Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug Metab. Pharmacokinet. 15 (1990), 1–5.
12. National Institute of Health, Dietary supplement database. (last accessed August 2017) https://dsld.nlm.nih.gov/dsld/rptQSearch.jsp?item=vinpocetine&db=adsld, 2017.
13. National Research Council, Guide for the Care and Use of Laboratory Animals. Eighth edition, 2011, The National Academic Press, Washington DC.
14. National Toxicology Program, Chemical information review document for vinpocetine [CAS No. 42971-09-5]. 2013.
15. Nie, S., Fan, X., Peng, Y., Yang, X., Wang, C., Pan, W., In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin. Arch. Pharm. Res. 30 (2006), 991–1001.
16. Pálosi, E., Szporny, L., Effects of ethyl apovincaminate on the central nervous system. Arzneim-Forsch (Drug Res) 26:10a (1976), 1926–1929.
17. Peruzza, M., DeJacobis, M., A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv. Ther. 3 (1986), 201–209.
18. Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. FASEB J. 22:3 (2008), 659–661.
19. Ribeiro, L.S.S., Falcão, A.C., Patrício, J.A.B., Ferreira, D.C., Veiga, F.J.B., Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine. J. Pharm. Sci. 96 (2004), 2018–2028.
20. Sitges, M., Aldana, B.I., Reed, R.C., Effect of the anti-depressant sertraline, the novel anti-seizure drug vinpocetine and several conventional antiepileptic drugs on the epileptiform EEG activity induced by 4-aminopyridine. Neurochem. Res. 41 (2016), 1365–1374.
21. Sozanski, T., Magdalan, J., Trocha, M., Szumny, A., Merwid-Lad, A., Slupski, W., Karazniewicz-Lada, M., Kielbowicz, G., Ksiadzyna, D., Szelag, A., Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats. Pharmacol. Rep. 63 (2011), 1258–1263.
22. Szatmári, S., Whitehouse, P., Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev., 1, 2003, CD003119, 10.1002/14651858.CD003119.
23. Taiji, H., Kanzaki, J., Clinical study of vinpocetine in the treatment of vertigo. Jpn. Pharmacol. Ther. 14 (1986), 577–589 (abstract in English).
24. Thal, L.J., Salmon, D.P., Lasker, B., Bower, D., Klauber, M.R., The safety and lack of efficacy of vinpocetine in Alzheimer's disease. J. Am. Geriatr. Soc. 37 (1989), 315–320.
25. Thorne Research, Inc, Monograph: vinpocetine. Altern. Med. Rev. 7 (2002), 240–243.
26. Truss, M.C., Stief, C.G., Ückert, S., Becker, A.J., Schultheiss, D., Machtens, S., Jonas, U., Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J. Urol. 18 (2000), 439–443.
27. Vereczkey, L., Pharmacokinetics and metabolism of vincamine and related compounds. Eur. J. Drug Metab. Pharmacokinet. 10 (1985), 89–103.
28. Vereczkey, L., Szporny, L., Metabolism of ethyl apovincaminate in the rat. Arzneimittelforschung 26:10a (1976), 1933–1938.
29. Vereczkey, L., Zólyomi, G., Szporny, L., Pharmacokinetic data on tritium labeled ethyl apovincaminate. Arzneim. Forsch. Drug Res. 26 (1976), 1929–1933.
30. Vereczkey, L., Szentirmay, Z., Szporny, L., Kinetic metabolism of vinpocetine in the rat. Arzneim. Forsch. Drug Res. 29 (1979), 953–956.
31. Vereczkey, L., Czira, G., Tamas, J., Szentirmay, Z., Botar, Z., Szporny, L., Pharmacokinetics of vinpocetine in humans. Arzneimittelforschung 29:6 (1979), 957–960.
32. Xia, H.M., Su, L.N., Guo, J.W., Liu, G.M., Pang, Z.Q., Jiang, X.G., Chen, J., Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 878 (2010), 1959–1966.
33. Xu, H., He, L., Nie, S., Guan, J., Zhang, X., Yang, X., Pan, W., Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J. Control. Release 140 (2009), 61–68.